apto-253
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01281592)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Myc proto-oncogene proteinINHIBITOR
MYC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1[nH]c2ccc(F)cc2c1-c1nc2c3cccnc3c3ncccc3c2[nH]1- Mol. weight
- 367.39 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297261 ↗
Also known as
- apto-253
- apto-253
- lor-253
- lor-253
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02267863 | Phase 1 | Oct 1, 2014 | Aptose Biosciences Inc. |
| NCT01281592 | Phase 1 | Jan 1, 2011 | Aptose Biosciences Inc., Cornell University, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptose Biosciences Inc. | For profit | 2 | 2 | 1 | 2011 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1